Roche Immunotherapy Combination Increases Lung Cancer Survival - Study | Latest News RSS feed

Roche Immunotherapy Combination Increases Lung Cancer Survival - Study - Latest News


Roche immunotherapy combination increases lung cancer survival-study

May 16 (Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination with... read more

Roche to present new positive data from its broad...

. Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Roche's latest advances and contributions to progress in cancer care will be fea... read more

Roche Holding Ltd (RHHBY) Management on Virtual Pipeline Event 2018 World Conference on Lung Cancer Conference Call (Transcript)

Roche Holding Ltd (OTCQX ... this is the study in non-small cell -- non-squamous non-small cell lung cancer; and it looks at the combination of pemetrexed with either carboplatin or cisplatin ... read more

Looking for another news?


F. Hoffmann-La Roche Ltd - Roche to present new positive data from its broad ...

Lung cancer: Key data to be presented at ESMO cover advances from Roche's lung cancer programme, including a combination approach using the cancer immunotherapy ... free survival (PFS) and safety anal... read more


Roche's (RHHBY) Study on Tecentriq for Lung Cancer Positive

Roche Holdings RHHBY ... IMpower133 is the first phase III study with an immunotherapy-based combination to show improvement in OS and PFS in the initial treatment of extensive-stage small cell lung c... read more

Study preserves hopes for Roche's Tecentriq in lung cancer

“These are the first positive Phase III survival results for any immunotherapy-based combination ... lung cancer,” Horning said. Roche shares were seen rising 1.1 percent, according to pre-market indi... read more

Roche reports very strong growth in the first nine months of 2018

In the US, sales increased ... lung cancer. Sales growth was driven by post-launch uptake in Europe, notably in Germany. Roche is conducting a large number of studies of Tecentriq in combination ... read more

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tec... read more

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche’s RHHBY member ... The Tecentriq study is the first phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival for the first-line treatment of advance... read more

Roche immunotherapy combination increases lung cancer survival-study

May 16 (Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination with... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us